content top

MH After Intravitreal Ranibizumab Injection for DME

Poster Jaeryung Oh Purpose: To report a case of macular hole formed after intravitreal ranibizumab injection in diabetic macular edema. Case summary: A 76-year-old woman with a 30-year history of type 2 diabetes visited the clinic presenting with the complaint of decreased vision in her right eye. The best-corrected visual acuity of the right eye was 6/20, and 6/12 in the left eye. Intraocular pressure was 20 mmHg in her right eye and she...

Read More

Expression Pattern of Extracellular Matrix Components After Ranibizumab for Neovascular ARMD

Poster Malgorzata Nita Purpose: The aim of the study was to evaluate the effect of loading doses of ranibizumab on gene expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in patients with CNV/AMD. Setting: Study was conducted by the Department of Ophthalmology, Medical University of Silesia, Independent Public Clinical Hospital, Katowice, Poland. Methods Inclusion criteria: patients ≥60...

Read More

Three Consecutive Loading Dose of Ranibizumab for the Treatment of Retinal Angiomatous Proliferation

Purpose: To evaluate the 12 months functional outcome and morphological changes according stages after 3 monthly intravitreal ranibizumab injections for the treatment of retinal angiomatous proliferation (RAP) in Korea. Methods: A retrospective chart review of 40 patients (41 eyes) with RAP was conducted. Patients received three initial monthly intravitreal injections (0.5 mg) of ranibizumab and monitored monthly for 12 months....

Read More

3 Cases of MH Following Intravitreal Injection with Ranibizumab

Poster Youngduk Kim Purpose: To report three cases of macular hole formation in patients who was administered intravitreal ranibizumab. Method: The first case was a 72-year-old man with age related macular degeneration and vitreomacular adhesion. The second case was a 76-year-old woman with subretinal haemorrhage and high PED. She was diagnosed with ARMD. The third case was 51-year-old woman with subretinal haemorrhage and high myopia....

Read More

Ocular Adverse Events Related to Intravitreal Ranibizumab in Patients with Exudative ARMD

Purpose: Anti-VEGF injections have been standard treatment of exudative age-related macular degeneration (ARMD) in recent years. However multiple and recurrent injections needed to maintain the efficacy of the treatment may lead to adverse side effects related to this regimen. The aim of this study was to find out ocular adverse events associated with intravitreal injection of ranibizumab for the treatment of exudative ARMD performed in a...

Read More

Effect of Intravitreal Ranibizumab on Cardiac Ischemic Parameters and Vascular Endothelial Function

Poster Altan Goktas Purpose: To evaluate the effect of intravitreal ranibizumab injection on cardiac ischemic parameters and vascular endothelial function. Methods: This observational, prospective case series included a total of 48 patients (23 patients with age-related macular degeneration and 25 patients with diabetic macular edema). All participants received intravitreal injections of 0.5 mg ranibizumab. Cardiac ischemic parameters...

Read More

Retinal Nerve Fiber Layer Thickness Change in Wet AMD Treated with Ranibizumab

Poster Ozen Ayranci Osmanbasoglu Advantages: To assess the effect of intravitreal (IV) ranibizumab therapy on retinal nerve fiber layer (RNFL) thickness. Methods: Fourteen eyes of 11 treatment naive patients with neovascular age related macular degeneration treated with ranibizumab were included. Patients were followed up by monthly examinations and IV ranibizumab injections were done as on needed basis. RNFL thickness s was measured by...

Read More

Treatment of Diabetic Macular Edema with Ranibizumab

Advantages: Intravitreal ranibizumab improves vision of patients with diabetic macular edema. Methods: Review of recent clinical trials such as DRCR.net. Effectiveness / Safety: DRCR trials showed that in patients with diabetic macular edema, intravitreal ranibizumab with prompt or deferred focal/grid laser had superior Visual Acuity outcome compared with focal/grid laser treatment alone. Take home message: Intravitreal ranibizumab is...

Read More

Intravitreal Ranibizumab Combined with Selective Laser Coagulation of Pigment Epithelium for Cystoid DME

Advantages: Selective laser coagulation of pigment epithelium (SLCPE) is effective laser procedure for treatment diffuse and focal diabetic macular edema with minimal damage of retina, but cystoid macular edema (CDME) is very torpid to different treatment modalities, and the majority of authors prefer grid laser for its treatment. We suggested that previous intravitreal ranibizumab (0.5 mg) will create conditions for effective SLCPE in...

Read More

Intravitreal Ranibizumab for Best’s Vitelliform Macular Dystrophy in a 38 Year-old Asian Woman

Advantages: To describe the effect of intravitreal ranibizumab for the treatment of choroidal neovascularisation and macular edema secondary to Best’s vitelliform macular dystrophy. Methods: A 38-year-old Asian woman with confirmed Best’s disease presented with decreased visual acuity (VA) due to secondary choroidal neovascularisation and macular edema. She was treated with a single intravitreal injection of ranibizumab (Lucentis, 0.5...

Read More

Combined Cataract Surgery and Intravitreal Ranibizumab in Preventing Postoperative ME in Non-proliferative Diabetic Retinopathy

Purpose: To evaluate the role of intravitreal ranibizumab, injected at the time of cataract surgery on the progression of postoperative diabetic macula edema (PME) in non-proliferative diabetic retinopathy (NPDR). Setting: Multi-center, prospective randomized study. Methods: 80 Patients with NPDR and cataract were randomized to 40 only cataract surgery (Sham group) or 40-cataract surgery plus intraoperative ranibizumab injection...

Read More

Ranibizumab for Residual Exudative Macular Detachment After PPV for Congenital Optic Pit

Advantages: Efficiency of surgical treatment of a macular detachment associated with an optic disc pit makes 63-100 %. However, possible recurrence of the disease and long (till 12 months) period of resorption of subretinal liquid after vitrectomy are, probably, responsible for the low functional results of operations. Methods: The purpose of our research was studying of efficiency of intravitreal injections in treatment for residual...

Read More

The Efficacy of Bevacizumab and Ranimizumab in Age-Related Macular Degeneration

Yong Sung You, Oh Kwon (Seoul, South Korea) Purpose: To compare the efficacy of Avastina and Lucentis in Neovascular AMD of Korean in South Korea. Materials and Methods: Retrospective, comparative study by reviewing the medical records of patients with wet AMD who were treated with anti-VEGF and followed up more than 6 months from January 2007 to November 2009. Results: 105 eyes (105 patients) were included. Avastin was injected in 32 eyes...

Read More

Proliferative Retinopathy Secondary to Chronic Lymphocytic Leukemia. The Role of Intravitreal Ranibizumab Prior to Pars Plana Vitrectomy

Ester Nuñez, Francisco J. Ascaso, Beatriz Jimenez, José A. Cristóbal (Zaragoza, Spain) Advantages: Retinal neovascularization is rare in patients with leukemia. To our knowledge, no case of chronic lymphocytic leukemia (CLL) has been associated with bilateral proliferative retinopathy. Intravitreal Ranibizumab facilitated the surgery reducing active neovascularization and intraoperative bleeding. Methods: We present the case report of a...

Read More

The Short Term Efficacy of Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema

Kyu Seo Kim, Dong Hyun Jee, Sang Hee Doh, Jae Hyung Park (Suwon, South Korea) Advantages: To evaluate the short-term effect of an intravitreal injection of ranibizumab in the treatment of diabetic macular edema. Methods: We retrospectively evaluated 18 eyes of 18 patients who underwent intravitreal ranibizumab injection for the treatment of diabetic macular edema between March 1 and November 30, 2009. Complete ophthalmic examinations...

Read More

Intravitreal Ranibizumab Combined with Verteporfin Photodynamic Therapy for Treating Polypoidal Choroidal Vasculopathy

Jung Yeul Kim (Daejeon, South Korea) Purpose: To evaluate the efficacy of intravitreal ranibizumab (Lucentis) with verteporfin photodynamic therapy (PDT) for patients with polypoidal choroidal vasculopathy (PCV). Patients and Methods: Seventeen eyes of 17 patients with symptomatic PCV who received three monthly intravitreal ranibizumab injections with PDT were retrospectively reviewed. The follow-up period lasted over 6 months after...

Read More

Ranibizumab or Photodynamic Therapy for Central Serous Chorioretinopathy?

http://www.evrs.eu/medias/2010/congress/Central-Serous-Chorioretinopathy.flv Begoña Pina Marín, José Juan Escobar Barranco, Manel Fernández Bonet (Barcelona, Spain) Advantages: The physiopathology of central serous corioretinopathy (CSC) remains controversial. The traditional treatment includes laser photocoagulation or photodynamic therapy (PDT). Lately, ranibizumab, an anti-VEGF antibody, has shown anti-permeable properties that...

Read More

Intravitreal Ranibizumab for Neovascular Age-Related Macular Degeneration

Ebru Demet Aygit, Çigdem Altan, Hülya Güngel (Istanbul, Turkey) Advantages: This study reports clinical outcomes of intravitreal Ranibizumab treatment for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and to identify predictive factors that may influence visual acuity (VA) outcomes. Methods: Thirty-one patients (32 eyes) with CNV were followed up at least 6 months after intravitreal injection (0,5 mg)...

Read More

Loading with Lucentis, Maintenance with Avastin: Can we Maintain the VA?

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Sengul C. Ozdek, Sibel Eryigit, Berati Hasanreisoglu (Ankara, Turkey) Purpose: To determine if PRN Bevacizumab can maintain the visual acuity (VA) gained with loading Ranibizumab for wet ARMD. Methods: The reports of patients with wet ARMD treated with 3 monthly Ranibizumab followed by PRN Bevacizumab were reviewed retrospectively. VA and central foveal thickness...

Read More

Three Year Results in Patients with Exudative Age-Related Macular Degeneration Using Constant Interval Dosing with Ranibizumab

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Mark E. Hammer, W. Sanderson Grizzard, Ivan J. Suner (Tampa, FL, USA) Advantages: Unlike the patients in the HORIZON study who lost vision after 2 years when they were switched to PRN dosing, our patients maintained their vision over three years. The recurrence rate in the PrONTO trial was 91.9%. Since recurrences cause visual loss, prevention of recurrences by...

Read More

Series of Three Ranibizumab Injections for the Treatment of Retrofoveolar Neovascular Age-Related Macular Degeneration, Two and a Half-Year Follow-Up

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Corinne Gonzalez (Toulouse, France) Advantages: Effective, efficient – Good functional results with same or less injections than protocol studies – secure but less restrictive follow-up – less recurrences, – more retinal protective, – lastly cheaper. Methods: 92 eyes of 81 patients, 25 men, 56 women, with retrofoveolar...

Read More

Use of High Definition OCT in Assessing the Effectiveness of Ranibizumab Intravitreal Injections in Patients with Exudative Age-Related Macular Degeneration

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Igor A. Malov, Sergey V. Nosov, N.S. Ponomaryova (Ekaterinburg, Russia) Advantages: Use of high definition OCT gives possibilities of better assessment of all retina layers after intravitreal Ranibizumab injections in patients with exudative Age-Related Macular Degeneration (ARMD). Methods: 10 eyes of 10 patients with wet ARMD were investigated. FAG confirmed...

Read More

Series of 3 Ranibizumab Injections, for the Treatment of Macular Retinal Telangiectasia Type 1 after One-Year Follow

http://www.evrs.eu/medias/2010/congress/Vascular-Pathologies-in-Young-Patients.flv Corinne Gonzalez (Toulouse, France) Advantages: Effective, efficiency – Good functional results, better than usual treatments – more retinal protective, no grid laser scars – less recurrences. Methods: 12 eyes of 12 patients, 10 men, 2 women, with Type 1 idiopathic macular telangiectasia. Patients received intravitreal Ranibizumab, 3 times,...

Read More

Half-Fluence Photodynamic Therapy Combined With Intravitreal Ranibizumab For Choroidal Neovascularization

Alay S. Banker, Ajay Dudani, Ashish Vaidya, Rohan Chauhan, Urvashi Goja Advantages: Combination therapies (half-fluence photodynamic therapy and intravitreal Anti-VEGF) lead to better chances of improved vision and fewer repeat treatments in cases of choroidal neovascularization. Methods: Prospective study of 36 eyes treated with single half-fluence Photodynamic therapy (PDT) + 3 monthly intravitreal ranibizumab (IL). ETDRS visual acuity...

Read More

Intravitreal Ranibizumab Treatment for Macular Diseases in Hong Kong: A Tertiary Eye Centre Experience

David T.L. Liu, Vincent Y.W. Lee, Chi-Lai Li, Alex H Fan, Dennis S.C. Lam Purpose: To report the indications and treatment outcomes of patients with macular diseases managed with intravitreal ranibizumab Setting: A prospective evaluation of consecutive cases series of macular diseases treated with intravitreal ranibizumab in a tertiary eye institute. Methods: Patients attending the macular treatment clinic at the Prince of Wales Hospital,...

Read More

Vision-specific Quality of Life at 12 Months in Subjects with or without Classic CNV Due to AMD: Phase III Clinical Trial of Ranibizumab (Lucentis)

Carl D. Regillo, MD, FACS (Philadelphia, PA),* Neil M. Bressler, MD (Baltimore, MD),* Jennifer T. Fine, PhD (South San Francisco, CA),* Chantal M. Dolan, PhD (South San Francisco, CA),* Claudine Marceau, PhD (Basel, Switzerland),* Tom S. Chang, MD (Pasadena, CA)* PURPOSE: To examine the effects of less frequent dosing of ranibizumab (LucentisTM) on patientreported visionspecific QoL through 12 months using the NEI-VFQ 25 in PIER, a phase...

Read More

Visual Outcome of Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration – Is Avastin Better Than Lucentis?

Charles E. Lyon, MD (Shreveport, LA), David H Ren, MD, PhD (Shreveport, LA) PURPOSE: To investigate the visual outcome of intravitreal bevacizumab in treating subfoveal choroidal neovascularization due to age-retlated macular degeneration. METHODS: An open label, nonrandomized, prospective observational study was done on patients with subfoveal choroidal neovascularization due to AMD regardless of lesion type and previous treatment. After...

Read More

Interim Results of the R.E.A.D. Study: Ranibizumab for Edema of the Macula in Diabetes

http://www.evrs.eu/medias/2006/congress/Interim-Results-of-the-R.E.A.D.-Study:-Ranibizumab-for-Edema-of-the-Macula-in-Diabetes.swf Diana V. Do, MD (Baltimore, MD), Quan Dong Nguyen, MD (Baltimore, MD),* Sinan Tatlipinar, MD (Denizli, Turkey), Syed Mahmood Shah, MBBS (Baltimore, MD), Pamela Singletary, COT (Baltimore, MD), Julia A. Haller, MD (Baltimore, MD),* Edward J. Quinlan, MD (Baltimore, MD), Jennifer U. Sung, MD (Baltimore, MD),...

Read More

Use of Double Reciprocal Analysis to Compare Pharmacological Treatments for Subfoveal Exudative AMD

Lucian V. Del Priore, MD, PhD (New York, NY), Ankoor R. Shah, BS (New York, NY) PURPOSE: Multiple pharmacological treatments (photodynamic therapy [PDT], Macugen, Lucentis, and Anecortave Acetate [AA]) exist for exudative AMD; typically these treatments are compared to controls in clinical trials but not to one another. We have shown the rate of visual loss in untreated eyes is linear on a double reciprocal Lineweaver-Burke (LB) plot with...

Read More

The Value and Cost-effectiveness of Interventions for Subfoveal, Neovascular, Age-related Macular Degeneration (ARMD)

http://www.evrs.eu/medias/2006/congress/The-Value-and-Cost-effectiveness-of-Interventions-for-Subfoveal,-Neovascular,-Age-related-Macular-Degeneration-(ARMD).swf Melissa M. Brown, MD, MN, MBA (Flourtown, PA),* Gary C. Brown, MD, MBA (Wyndmoor, PA)* PURPOSE: To assess the value of interventions utilized for the treatment of subfoveal, neovascular, agerelated macular degeneration (ARMD) employing evidencebased data from clinical trials...

Read More

Vision-specific Quality of Life at 12 Months in Predominantly Classic Neovascular AMD in ANCHOR: A Phase III Trial of Ranibizumab and Verteporfin PDT

Neil M. Bressler, MD (Baltimore, MD), Chantal M. Dolan, PhD (South San Francisco, CA),* Jennifer Fine, ScD (South San Francisco, CA),* Claudine Marceau, MBA, MSc (Basel, Switzerland),* Tom S. Chang, MD (Pasadena, CA)* PURPOSE: To examine the effects of ranibizumab (LucentisTM) on patient-reported vision-specific quality of life (QoL) using the NEI-VFQ 25 through 12 months in subjects with predominantly classic subfoveal choroidal...

Read More

Survey of Current and Future Avastin Usage: Emphasis on Economics

Gregory R. Blaha, MD, PhD (Peabody, MA), Tom C. Hsu, MD (Peabody, MA), Paul L. Lee, MD, JD (Durham, NC), Brendan E. McCarthy, MD (Peabody, MA), Jeffrey L. Marx, MD (Peabody, MA)* PURPOSE: To assess current and expected future usage patterns of Avastin (bevacizumab, Genentech) among retinal physicians with emphasis on economic factors. METHODS: Surveys were mailed in January 2006 to all 1,245 retinal physicians in the United States as...

Read More

Ranibizumab (LucentisTM) Vision-specific Quality of Life through 24 Months in Neovascular AMD Subjects in MARINA: A Phase III Clinical Trial

http://www.evrs.eu/medias/2006/congress/Ranibizumab-(LucentisTM)-Vision-specific-Quality-of-Life-through-24-Months-in-Neovascular-AMD-Subjects-in-MARINA:-A-Phase-III-Clinical-Trial.swf Tom S. Chang, MD (Pasadena, CA),* Jennifer T. Fine, PhD (South San Francisco, CA),* Chantal M. Dolan, PhD (San Francisco, CA),* Claudine Marceau, PhD (Basel, Switzerland),* Neil M. Bressler, MD (Baltimore, MD)* PURPOSE: To examine the effects of ranibizumab...

Read More

Open-label, Multicenter, Phase II Study Assessing the Safety and Efficacy of Same-day Verteporfin and Liquid Ranibizumab 0.5mg (PROTECT Study)

Sebastian Wolf, MD (Bern, Switzerland),* Thomas C. Hohman, PhD (East Hanover, NJ),* PROTECT Study Group PURPOSE: To evaluate the safety and explore the efficacy of same-day administration of verteporfin and intravitreal injection of liquid ranibizumab 0.5mg. METHODS: PROTECT is an open label, multicenter, Phase II, 9 month study, in patients with predominantly classic (n=13) or occult (n=19), subfoveal CNV secondary to AMD. Verteporfin was...

Read More

An OCT-guided Variable-dosing Regimen with LucentisTM (Ranibizumab) in Neovascular AMD: One Year Results from the PrONTO Study

http://www.evrs.eu/medias/2006/congress/An-OCT-guided-Variable-dosing-Regimen-with-LucentisTM-(Ranibizumab)-in-Neovascular-AMD:-One-Year-Results-from-the-PrONTO-Study.swf Philip J. Rosenfeld, MD, PhD (Miami, FL),* Carmen A. Puliafito, MD, MBA (Miami, FL),* Anne E. Fung, MD (San Francisco, CA),* Geeta A. Lalwani, MD (Miami, FL), Stephan Michels, MD (Vienna, Austria),* William J. Feuer, MS (Miami, FL) PURPOSE: To determine if an OCT-guided...

Read More

Correlation of Optical Coherence Tomography and Retinal Angiography in Patients Treated with Bevacizumab for Choridal Neovascular Membrane

Swati Agarwal, MD (Jacksonville, FL), Shailesh Gupta, MD (Jacksonville, FL), Sandeep Grover, MD (Jacksonville, FL), K.V. Chalam, MD, PhD (Jacksonville, FL), Sweta Tarigopula, BS (Jacksonville, FL) PURPOSE: To correlate the optical coherence tomography and Heidelberg retinal angiography findings in patients treated with intravitreal bevacizumab for choroidal neovascular membranes. METHODS: 12 patients with choroidal neovascular membranes...

Read More

PIER: Year 1 FA/OCT Results in a Study of Ranibizumab (LucentisTM) for Choroidal Neovascularization (CNV) Due to Agerelated Macular Degeneration (AMD)

http://www.evrs.eu/medias/2006/congress/PIER:-Year-1-FA-OCT-Results-in-a-Study-of-Ranibizumab-(LucentisTM)-for-Choroidal-Neovascularization-(CNV)-Due-to- Agerelated-Macular-Degeneration-(AMD).swf William F. Mieler, MD (Chicago, IL) PURPOSE: PIER is a 2-year study of the safety/efficacy of 0.3-and 0.5mg doses intravitreal ranibizumab, injected monthly for 3 doses and then every 3 months, vs. Sham injections in AMD patients with CNV lesions...

Read More

PIER: Year 1 Results of a Phase IIIB Study of Ranibizumab Efficacy and Safety in Choroidal Neovascularization Due to Age-related Macular Degeneration

http://www.evrs.eu/medias/2006/congress/PIER:-Year-1-Results-of-a-Phase-IIIB-Study-of-Ranibizumab- Efficacy-and-Safety-in-Choroidal-Neovascularization-Due-to-Age-related-Macular-Degeneration.swf Prema Abraham, MD (Rapid City, SD),* Huibin Yue, PhD (South San Francisco, CA),* Naveed Shams, MD, PhD (South San Francisco, CA)* PURPOSE: PIER is a 2-year study of the safety and efficacy of intravitreal injections of 2 different doses (0.3 and 0.5...

Read More

Intravitreal Ranibizumab (LucentisTM) Plus Verteporfin Photodynamic Therapy for Neovascular Age-related Macular Degeneration: FOCUS 2-year Results

http://www.evrs.eu/medias/2006/congress/Intravitreal-Ranibizumab-(LucentisTM)-Plus-Verteporfin- Photodynamic-Therapy-for-Neovascular-Age-related-Macular- Degeneration:-FOCUS-2-year-Results.swf Andrew N. Antoszyk, MD (Charlotte, NC),* Debbi Kotlovker, (San Francisco, CA),* Sharon O’Byrne, (San Francisco, CA)* PURPOSE: The 2-year FOCUS study compared the safety and efficacy of monthly intravitreal injections of ranibizumab (Lucentis) in...

Read More

Consistency of Effect of Ranibizumab at 2 Doses on Contrast Sensitivity in 3 Phase III and IIIB Studies of Patients with CNV Secondary to AMD

http://www.evrs.eu/medias/2006/congress/Consistency-of-Effect-of-Ranibizumab-at-2-Doses-on-Contrast- Sensitivity-in-3-Phase-III-and-IIIB-Studies-of-Patients-with-CNV- Secondary-to-AMD.swf Jean-Francois Korobelnik, MD (Bordeaux, France)* PURPOSE: To examine the consistency of effect of intravitreal ranibizumab on contrast sensitivity in three populations of patients with different subtypes of choroidal neovascular lesions: predominantly...

Read More

Two-year Efficacy and Safety Results from the MARINA Study

http://www.evrs.eu/medias/2006/congress/Two-year-Efficacy-and-Safety-Results-from-the-MARINA-Study.swf Ursula Schmidt-Erfurth, MD (Vienna, Austria), George A.Williams, MD (Royal Oak, MI), for the MARINA Study Group PURPOSE: The MARINA study is a 2-year, Phase III, multicenter, randomized, double-masked, sham injectioncontrolled study designed to evaluate the efficacy and safety of monthly intravitreal injections of ranibizumab used as a...

Read More

Ranibizumab (Lucentis) in Ischemic Central Retinal Vein Occlusion: Interim OCT and Visual Results from the RAVE Trial

Matthew S. Benz, MD (Houston, TX),* David M. Brown, MD (Houston, TX),* Richard H. Fish, MD (Houston, TX),* Rosa Y. Kim, MD (Houston, TX),* Andrew Strickler, MS (Houston, TX), Tien P. Wong, MD (Houston, TX)* PURPOSE: Patients with ischemic central retinal vein occlusion have a high rate of developing anterior segment neovascularization and neovascular glaucoma and often have a dismal visual outcome. The RAVE (Rubeosis Anti-VEGF) study is an...

Read More

Combined Safety of Intravitreal Ranibizumab in Two Phase III Studies of Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Paolo Lanzetta, MD (Udine, Italy),* MARINA and ANCHOR Study Groups PURPOSE: To examine the consistency of safety across two studies of ranibizumab in three populations of patients with different subtypes of choroidal neovascular lesions: predominantly classic, minimally classic and occult lesions with no classic component. METHODS: Ranibizumab has been tested in 2 Phase III, randomized, multicenter, double-masked, controlled studies of...

Read More

Combined Efficacy of Intravitreal Ranibizumab in Two Phase III Studies of Choroidal Neovascularization Secondary to Age-related Macular Degeneration

http://www.evrs.eu/medias/2006/congress/Combined-Efficacy-of-Intravitreal-Ranibizumab-in-Two-Phase-III-Studies-of-Choroidal-Neovascularization-Secondary-to-Age-related-Macular-Degeneration.swf Anat Loewenstein, MD (Tel Aviv, Israel),* MARINA and ANCHOR Study Group PURPOSE: Is Ranibizumab effective in the treatmentof CNV secondary to AMD? METHODS: Ranibizumab has been tested in two Phase III,randomized, multicenter, double-masked, controlled...

Read More
content top